Molecular Imaging Versus Adrenal Vein Sampling for the Detection of Surgically Curable Primary AldosteronismEmily Goodchild, Morris J. Brown, Daniel M. Berney et al.|Annals of Internal Medicine|2025Cited by 26
Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trialGiulia Argentesi, Xi‐Lin Wu, Alexander Ney et al.|The Lancet|2025Cited by 25
A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[<sup>18</sup>F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary AldosteronismDaniel Gillett, Mark Gurnell, Russell Senanayake et al.|Journal of Nuclear Medicine|2025Cited by 11
Novel radiolabeled ligand, Para-chloro-2-[<sup>18</sup>F]fluoroethyletomidate (CETO) compared to [<sup>11</sup>C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)Emily Goodchild, Morris J. Brown, Russell Senanayake et al.|Endocrine Abstracts|2022Cited by 1
Preliminary data from FABULAS: a Feasibility study of RadioFrequency endoscopic ABlation, with ULtrasound guidance, as a non-surgical, Adrenal Sparing treatment for aldosterone producing adenomasGiulia Argentesi, Brown Morris J., Xi‐Lin Wu et al.|Endocrine Abstracts|2022Cited by 1